# Tiziana Life Sciences (TLSA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TLSA
## Company Profile
- Ticker: TLSA
- Exchange: NASDAQ
- Sector: MedTech
- Location: United Kingdom and trades in the U
- Tags: MedTech, Oncology, Immunology
## Stock Data
- Close: 1.11 USD
- Market cap: 173072418.16000003 USD
- Last updated: 2026-10-06
## Business Overview
Tiziana Life Sciences is a biotechnology company focused on immune modulation and respiratory or inflammatory disease applications. Its story centers on using biologic or cellular approaches to influence difficult disease pathways.
## Why The Stock Is Moving

As of Oct 6, 2026, TLSA closed up 3.74% at $1.11. No new same-company headline was identified in the current news window.

## Geographic Base

Tiziana is headquartered in the United Kingdom and trades in the U.S. market. It sits in small-cap biotechnology.

## Business Model

The company depends on translational progress, clinical validation, and strategic focus across a narrow pipeline. Investors usually watch early data and whether the platform can sharpen its therapeutic thesis.

## Landscape Position

Tiziana occupies a niche immune-modulation position within biotech. It is a catalyst-driven small-cap name where scientific proof matters more than commercial scale.

## Future Catalysts

- Tiziana’s catalysts are foralumab and the neuro / autoimmune programs, with any update that clarifies whether the platform can still progress. The market will want a cleaner clinical path.

## Recent News
- 2026-09-30 11:00 EST — [Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)](https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-files-for-orphan-drug-designation-with-the-fda-for-intrana-f526ed5c) — Source: Tiziana Life Sciences
- 2026-09-28 11:00 EST — [Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab](https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-first-participants-dosed-in-als-banyan-clinical--655c1865) — Source: Tiziana Life Sciences
- 2026-09-21 11:00 EST — [Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab](https://biopharmsignal.com/news/TLSA/tiziana-announces-last-patient-completes-last-visit-in-phase-2a-inform-ms-trial--159ac753) — Source: Tiziana Life Sciences
- 2026-09-17 11:00 EST — [Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center](https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-signing-of-mou-with-king-abdullah-international--9e1ddb58) — Source: Tiziana Life Sciences
- 2026-08-24 11:00 EST — [Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026](https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-poster-presentation-on-phase-2a-banyan-clinical--05b3ab0b) — Source: Tiziana Life Sciences